Target
$361.59 → $361.21
Public companyResearch currentFresh
Stryker
Intervene · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Intervene exposure in Healthspan Infrastructure.
Intervene / Orthopedics, Mako robotics: Stryker controls the robotic-assisted joint-replacement ecosystem through Mako SmartRobotics. The bottleneck is not the robot (a one-time ~$1.0–1.5M capital sale) — it is the implant + disposable pull-through the robot locks in: Mako's preoperative CT-planning, intraoperative haptic-guided cutting, and postoperative data workflow make the surgeon/hospital standardize on Stryker implants, instruments, and disposables. The robot is the razor; the implant is the blade.
Catalysts
Stryker Q2 2026 earnings; Mako robotic-assisted surgery procedures; orthopedics demand recovery; neurovascular portfolio; AI-enabled surgery tools
Invalidation
Thesis weakens if Mako stays orthopedics-only as robotics consolidates toward soft-tissue platforms, Ortho Tech growth decelerates below ~10.5%, or $158M one-time tariff reversal + ~$400M tariff headwind compress margins. (vault 2026-08)
Latest change
· Conviction moved from 2 to 3.
Research history
See all SYK changes Earlier changes
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
| Fund / investor | As of | Fund portfolio weight | Evidence |
|---|---|---|---|
| iShares U.S. Medical Devices ETF IHI | 4.72% | Source |
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
ins+$0.0M(5buy) · 13F 15+/10-×0.0 · short↑0.36
Current snapshotNeutral — No investor/analyst mentions of the company found. [X search Aug 2026]
Lower-confidence snapshotTarget price: $350.82
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Moat Durability
- Capacity cycle
- Toll Road Tier
- Strong proxy
Timestamped research update
Deep research update
2,783 words · Updated 19 Oct 2026 · 6 sources
Q2 2026 (10-Q filed 2026-07-31, CIK 0000310764) and FY2025 (10-K):
| Metric | FY2025 | Q2 2026 |
|---|---|---|
| Net sales | $25.116B | $6.589B (+9.4% YoY, ~9.0% organic) |
| Gross profit | $16.065B | $4.498B (~68.3%, incl. $158M one-time tariff reversal) |
| Operating income | $4.889B | $1.659B |
| Adj. operating margin | — | 27.4% (+170 bps) |
| Adj. EPS | — | $3.69 (+17.9% YoY) |
- monetization model: one-time capital hardware + recurring consumables/instruments + implants + services; mix of capital, consumables, and service (10-K Item 1; acc. 0000310764-25-000010; sec.gov )
- revenue mix: MedSurg & Neurotechnology ~57%; Orthopaedics ~43% (FY2024 segment note; acc. 0000310764-25-000010; sec.gov )
- who pays: hospitals/health systems, ASCs, surgeons, distributors, government/military hospitals; payers reimburse (10-K Item 1; acc. 0000310764-25-000010; sec.gov )
- margin_value_capture: FY2024 GAAP gross margin ~64%; GAAP operating margin ~19% (10-K financials; acc. 0000310764-25-000010; sec.gov )
- customer classes: Health Systems & Providers, ambulatory surgery centers, surgeons, distributors, government/military hospitals, Payers & Insurers (reimbursement) (10-K Item 1; acc. 0000310764-25-000010; sec.gov )
Stryker is a global medical technology company that designs, manufactures, and sells medical devices and equipment. Its business is organized into two reportable segments:
- MedSurg and Neurotechnology
- Orthopaedics and Spine
This segmentation is disclosed in Stryker’s Form 10-K for fiscal year 2023, on file with SEC EDGAR under CIK 0000310764. The segment structure is relevant because the two segments have different margin profiles, recurring-revenue characteristics, and exposure to hospital capital spending versus procedure volumes.
The table below uses figures drawn from Stryker’s 10-K for FY2023 and FY2022. These figures should be re-pulled from the actual filing before being used in any investment memo. Exact accession numbers are flagged as needs primary source validation.
| Segment | FY2023 net sales | Share of FY2023 net sales | FY2022 net sales | Share of FY2022 net sales |
|---|---|---|---|---|
| MedSurg and Neurotechnology | $11,885 million | ~58.0% | $10,655 million | ~57.8% |
| Orthopaedics and Spine | $8,613 million | ~42.0% | $7,794 million | ~42.2% |
| Total Stryker net sales | $20,498 million | 100% | $18,449 million | 100% |
Based on the 10-K Business section, Stryker sells to:
- Hospitals and hospital systems: purchasing operating room equipment, implants, beds, and service contracts.
- Ambulatory surgery centers: buying implants and instruments for outpatient joint replacement and sports medicine procedures.
- Physicians and surgeons: although the hospital often purchases, surgeons influence or specify the implant system.
- Group purchasing organizations: negotiate national or regional contracts on behalf of hospitals.
- Emergency medical services and government buyers: for patient handling and emergency equipment.
The specific buyer categories in the filing should be confirmed by pulling the Business section text.
Stryker’s customer base is broad. The 10-K likely states that no single customer accounts for more than 10% of net sales. If confirmed, this lowers single-customer concentration risk. However, this claim is based on my model’s recall and must be treated as needs primary source validation until the exact 10-K sentence is located.
Stryker is heavily exposed to the United States. My model recall is that U.S. sales were approximately 74% of total net sales in FY2023, with international sales around 26%. This figure should be pulled from the 10-K geographic disclosure. If true, it means:
- U.S. hospital capital spending and U.S. reimbursement policy drive most of the revenue base.
- Currency translation affects the international portion, visible in the organic growth bridge.
- SYK requires verified SEC financials and competitor filing checks before conviction changes.
- SYK requires verified SEC financials and competitor filing checks before conviction changes.
| Parameter | Value | Source | Confidence |
|---|---|---|---|
| Mako installed base | ~3,000+ systems | Mgmt/analyst commentary (Q2 2026) | inferred |
| Cumulative Mako procedures | ~2M+ | Mgmt/analyst commentary (Q2 2026) | inferred |
| Mako robot ASP | ~$1.0–1.5M | Industry / capital equipment pricing | assumed |
| Per-procedure implant + disposable pull-through | ~$7–8K (knee implant ~$5–7K + Mako disposables/cutting guides ~$1–1.5K) | Razor-razorblade model | derived |
| Procedures / system / year (current run-rate) | ~150–250 | 2M cumulative ÷ 3,000 systems = ~667 avg; current run-rate higher | derived |
| FY2025 total revenue | $25.116B | SEC 10-K, XBRL us-gaap:Revenues | measured |
| Q2 2026 revenue | $6.589B (+9.4% reported, ~9.0% organic) | SEC 10-Q + earnings | measured |
| Q2 2026 gross profit / margin | $4.498B / ~68.3% (incl. $158M tariff reversal) | SEC XBRL | measured |
| Q2 2026 adjusted operating margin | 27.4% (+170 bps YoY) | Q2 2026 earnings | measured |
| FY2026 organic growth guidance | 8.3–9.3% (raised) | Q2 2026 earnings | measured |
- Revenue, margin, and backlog figures: needs primary source validation.
- Competitor filings should be checked for demand, pricing, and share-shift contradictions.
- Revenue, margin, and backlog figures: needs primary source validation.
- Competitor filings should be checked for demand, pricing, and share-shift contradictions.
| Parameter | Value | Source | Tier | Measured/derived/assumed | Cross-verified |
|---|---|---|---|---|---|
| FY2023 net sales | $20,498 million | Stryker 10-K FY2023, SEC EDGAR CIK 0000310764 | Tier 1 | Measured | Single-source in this note |
| FY2023 MedSurg and Neurotechnology sales | $11,885 million | Stryker 10-K FY2023 | Tier 1 | Measured | Single-source |
| FY2023 Orthopaedics and Spine sales | $8,613 million | Stryker 10-K FY2023 | Tier 1 | Measured | Single-source |
| FY2023 gross margin | ~63.6% | Stryker 10-K FY2023 | Tier 1 | Derived | Single-source |
| FY2023 operating margin | ~18.1% | Stryker 10-K FY2023 | Tier 1 | Derived | Single-source |
| FY2023 net margin | ~15.4% | Stryker 10-K FY2023 | Tier 1 | Derived | Single-source |
| FY2023 reported sales growth | ~11.1% | Stryker 10-K FY2023 MD&A | Tier 1 | Derived | Single-source |
| FY2023 organic sales growth | ~11.0% | Stryker 10-K FY2023 MD&A | Tier 1 | Derived | Single-source |
| FY2023 effective tax rate, approximate | ~19% | Stryker 10-K FY2023 income statement | Tier 1 | Derived | Single-source |
| FY2023 Zimmer Biomet net sales | $7,394 million | Zimmer Biomet 10-K FY2023, SEC EDGAR CIK 0001136869 | Tier 1 | Measured | Single-source |
Every numeric value in this table should be re-pulled from the actual filings before use. If the exact filing metadata cannot be resolved, treat each value as needs primary source validation.
Stryker controls the robotic-assisted joint-replacement ecosystem through Mako SmartRobotics. The bottleneck is not the robot (a one-time ~$1.0–1.5M capital sale) — it is the implant + disposable pull-through the robot locks in: Mako's preoperative CT-planning, intraoperative haptic-guided cutting, and postoperative data workflow make the surgeon/hospital standardize on Stryker implants, instruments, and disposables. The robot is the razor; the implant is the blade. A hospital that buys a Mako becomes a recurring Stryker implant account for the ~7–10 year life of the system.
- Installed base: 3,000+ Mako systems globally; 2M+ cumulative procedures performed (management/analyst commentary via Q2 2026 earnings — inferred, not a 10-Q line item).
- Record Q2 2026 placements — "best-ever" install quarter with an elevated hospital capital backlog (management commentary, Q2 2026 call).
- Ortho Tech reorg (Q1 2026): Stryker folded Mako + orthopaedic instruments + power tools + enabling technologies into a single "Ortho Tech" business — a structural signal that robotics is now the strategic center of the ortho franchise (10-Q MD&A, filed 2026-07-31).
- Platform expansion: full market release of Mako RPS (handheld robotic system for total knee in ambulatory surgery centers / ASCs) and Mako 4 / V4 ("home run" per analysts) — 2026.
- Clinical moat: UK registry data shows ~46% lower revision risk for Mako partial knee over 9 years — registry evidence that raises the bar for any competitor's value proposition (analyst-cited registry, inferred).
- FDA-cleared ecosystem: instruments, implants, and software designed as a closed system; switching requires full re-validation of the surgical workflow.
Stryker is a Healthspan → Intervene name, so this is the doctrine's universal three-question test. The moat under test is the Mako SmartRobotics implant-pull-through ecosystem (robot = razor, implant/disposable = blade), not Stryker's broader ~$25B diversified med-tech franchise.
| Test | Score (1–3) | Rationale (cited) |
|---|---|---|
| Bypass | 2 (partial) | Hospitals can substitute — Zimmer Rosa, Globus ExcelsiusGPS, Smith+Nephew Cori, JNJ Velys all field robotic-ortho systems. But switching off Mako costs ~$2–3M + 6–12 months of re-training/re-validation (note's 08-16 worked switching-cost model) and forfeits the ~46%-lower-revision UK registry data. Partial, not total, bypass. |
| Concentration | 2 (strong, not sole) | Mako is the #1 robotic-ortho installed base (3,000+ systems, 2M+ procedures) with ~8–9× implant/disposable pull-through — a real value-chain chokepoint in orthopedics. But it is an oligopoly, not a monopoly: 4 credible competitors hold material share, so buyers retain alternatives. |
| Hyperscaler exposure | 3 (none) | Medical robotics/implants are FDA-regulated, physically-implanted workflows — outside AWS/Azure/GCP/Google scope. No hyperscaler bundle threat (unlike observability/identity). |
Composite = 2 + 2 + 3 = 7 → STRONG PROXY. This confirms the resident STRONG_PROXY tier (the tier was correct; only the score + sub-scores were unwritten). It is not a DIRECT BOTTLENECK (8–9): the robotics hardware is replicable and there are credible substitutes — the scarcity is the installed-base annuity + registry/clinical data + FDA-cleared closed workflow, not the physics. Consistent with the note's own verdict: consensus compounder, not an under-owned asymmetric bet.
- Mako Robotic Power System — commercial launch (Aug 2026, stock rose on the news). A powered-instrument/actuation extension of the Mako ecosystem — deepens the razor/razorblade pull-through (more disposables/instruments per procedure). Source: Morningstar SYK news feed ("Stryker Shares Rise After Commercial Launch of Mako Robotic Power System").
- SportSuite Vision — FDA De Novo authorization + first clinical use (mixed-reality hip surgery). Extends the digital-surgery footprint beyond robotics into intraoperative AR navigation; early, but reinforces the closed-workflow moat. Source: Simply Wall St ("The Bull Case For Stryker Could Change Following Its Mixed-Reality Hip Surgery Milestone").
- SmartCare unit — Stryker merged Vocera + Care AI into a new SmartCare unit on a modern cloud stack (hospital "operating system" + AI). CEO Kevin Lobo flagged "really big second half of sales growth." This is the non-robotics AI vector; additive to, not a replacement for, Mako. Source: 24/7 Wall St. / Yahoo Finance (2026-09-04).
- Inari backorder resolution by Q3 flagged as a key inflection — the Peripheral-Vascular supply disruption (Vascular −0.4% in Q2) is a near-term headwind to watch. Source: Yahoo Finance (2026-09-04).
technical_scarcity6.0 → 8,economic_capture2.0 → 7,time_to_monetize4.0 → 6 (note's 08-16 differentiated integers, re-affirmed: ts 8 = installed-base annuity + registry + closed ecosystem minus replicable hardware; ec 7 = ~8–9× pull-through + 68% GM + 27.4% OM minus consensus-priced; ttm 6 = Mako RPS/V4 + Robotic Power System + SmartCare are H2-2026 catalysts already in a ~21× fwd P/E).toll_road_scoreNULL → 7;bypass_test_score2 /concentration_test_score2 /hyperscaler_exposure_score3;toll_road_tier= STRONG_PROXY (confirmed).thesis_statusNEEDS_MORE_DATA → INTACT (matches the note verdict).convictionleft at 1.0 (panel/advisor-owned field) — flagged for panel: the 08-16 note Log records "INTACT with conviction 3/5 (WATCH)" vs. DB 1.0; the panel should reconcile this divergence separately.
| # | Source | Date | Type |
|---|---|---|---|
| 1 | SEC submissions CIK 0000310764 (fresh-filing check: only Form 4/144 since 07-31) | 2026-09-06 | SEC API |
| 2 | Morningstar SYK news feed — Mako Robotic Power System commercial launch | 2026-08 | News |
| 3 | Simply Wall St — SportSuite Vision FDA De Novo + first clinical use | 2026-09 | News |
| 4 | 24/7 Wall St. / Yahoo Finance — Intuitive vs. Stryker (SmartCare unit, Inari backorder, H2 "regained momentum") | 2026-09-04 | News |
| 5 | Note 08-16 block — worked pull-through + switching-cost models (re-affirmed) | 2026-08-16 | Vault |
- product_service: orthopaedic implants, robotic surgery (Mako), surgical/endoscopic equipment, neurotechnology/neurovascular, spine, emergency care (10-K Item 1; acc. 0000310764-25-000010; sec.gov )
- technical function: restores joint function; robotic-arm assisted bone resection; powered tools; visualization; neurovascular stroke devices; spinal fixation (10-K Item 1; acc. 0000310764-25-000010; sec.gov )
- why it is hard: FDA 510(k)/PMA/regulatory clearances, surgeon training/switching costs, hospital capital install base, clinical evidence, IP/scale (10-K Item 1 & 1A; acc. 0000310764-25-000010; sec.gov )
- substitutes: Zimmer Biomet, DePuy Synthes/J&J, Smith & Nephew, Medtronic, B. Braun, Arthrex; non-surgical care; generic implants (10-K Item 1 Competition; acc. 0000310764-25-000010; sec.gov )
- pricing power: MED — GPO/IDN contracting and reimbursement pressure, offset by differentiated Mako/robotics and implant pull-through (10-K Item 1A; acc. 0000310764-25-000010; sec.gov )
Stryker’s two segments contain multiple product franchises.
Stryker has some pricing power in premium implant and technology categories, particularly categories with surgeon preference and robotic integration. But pricing power is constrained by:
- Group purchasing organization negotiations.
- Hospital cost-containment pressure.
- Medicare and private payer reimbursement changes.
- Competition from lower-cost implants in commoditized categories.
The 10-K risk factors contain warnings about pricing pressure and reimbursement. The gross margin of roughly 63.6% indicates the company has meaningful product-level profitability, but that does not by itself prove pricing power. A better evidence set would require price/mix disclosures from the 10-K MD&A, which my current note cannot fully verify.
- Zimmer Biomet (ZBH) — Rosa: the most direct robotic-ortho competitor, but a fraction of Mako's installed base and procedure share.
- Globus Medical (GMED) — ExcelsiusGPS: strong in spine robotics; cross-selling into ortho.
- Smith+Nephew (SNN) — Cori: handheld robotic UKA platform; niche.
- Johnson & Johnson (JNJ) — Velys: robotic-assisted knee via DePuy Synthes; distribution heft but later entrant.
- Intuitive Surgical (ISRG) / Medtronic (MDT) Hugo: soft-tissue/general surgery — adjacent, not direct, but they cap Stryker's robotic TAM to orthopedics.
- Internal disruption risk: Mako RPS (handheld, lower-ASP) could cannibalize the premium cart-based Mako in ASC settings — Stryker is deliberately trading some per-unit ASP for ASC penetration.
- $158M one-time tariff reversal inflated Q2 gross margin — strip it and the "beat" is thinner than headline GM suggests.
- Stock fell ~7% on the Q2 print despite the beat — the market already prices in Mako momentum; this is a crowded consensus compounder, not an under-owned asymmetric bet.
- Mako is orthopedics-only — if robotic surgery consolidates toward soft-tissue/general platforms, Stryker's TAM is structurally capped.
- If Ortho Tech growth decelerates below the ~10.5% Q2 rate once the reorg comps normalize, the robotics narrative loses its engine.
- ~$400M tariff headwind + Peripheral Vascular supply disruption (Vascular −0.4% in Q2) — near-term operational drags.
- ASC/handheld shift (Mako RPS) risks ASP compression if hospitals substitute the cheaper handheld for the full cart system.
What would prove the Stryker thesis wrong? I would treat at least the following as disconfirming:
- Procedure volume decline: If U.S. hip/knee/spine procedure volume declines due to macroeconomic pressure, Medicare eligibility changes, or a pandemic-type disruption, Stryker’s Orthopaedics and Spine segment would slow. Stryker’s 10-K risk factors discuss procedure volumes and hospital capacity.
- Hospital capital spending freeze: If hospitals delay capital purchases of beds, endoscopy towers, or Mako robots, MedSurg and Neurotechnology growth could miss expectations.
- Reimbursement cuts: Medicare or private payer reductions for joint arthroplasty, spine surgery, or outpatient procedures would pressure implant pricing and hospital budgets.
- Mako utilization decline: If Mako robot placements stall or existing systems are underused, the expected implant pull-through would not materialize.
- Competitive robotic system gains: If Zimmer Biomet ROSA, J&J VELYS, or Smith+Nephew CORI demonstrate superior clinical or workflow outcomes, Stryker could lose share in robotic-assisted orthopaedics.
- Price erosion accelerates: If GPOs or hospital systems force meaningful price cuts, Stryker’s 63.6% gross margin could compress faster than expected.
- Supply chain or raw material shocks: Titanium, cobalt-chrome, resins, and electronics input cost spikes could hurt margins.
- Acquisition integration failure or goodwill impairment: Stryker has grown through acquisitions. A poorly integrating acquisition or a large goodwill impairment would signal NPV destruction.
- Regulatory or quality-system failure: A Class I recall, FDA warning letter, or consent decree involving Stryker manufacturing could damage reputation and revenue.
- Foreign exchange headwind: If the U.S. dollar strengthens materially, international revenue translation would reduce reported sales, though organic growth would strip that out.
These are drawn from the general category of risks in medical device 10-K filings and should be re-verified against Stryker’s specific Risk Factors section.
- What is Stryker's confirmed (not analyst-estimated) current installed-base and annual-procedure count? The 3,000+ / 2M+ figures are management-commentary, not 10-Q line items.
- Is Ortho Tech's ~10.5% growth sustainable, or an artifact of the Q1 2026 reorg reclassification?
- Does Mako RPS cannibalize the premium cart-based Mako ASP, and at what ASC penetration rate does that margin trade-off turn negative?
- Will Stryker build or buy a soft-tissue robotics capability to extend the moat beyond orthopedics?
Primary and supporting material
Sources
6 sources preserved from the latest qualified research update.